Global law firm Goodwin today announced that Pavel Shaitanoff joined the Private Equity practice as partner, resident in the New York office. Shaitanoff joins the firm from Gibson, Dunn & Crutcher LLP.
“Pavel joins our growing global team as our clients remain extraordinarily busy pursuing innovation-driven investment opportunities,” said A.J. Weidhaas, co-chair of Goodwin’s Private Equity practice. “Pavel is a skilled dealmaker with a strong background that aligns closely with the needs of our clients and complements the strengths of our platform. We’re thrilled to have him on board.”
Shaitanoff advises private equity and corporate strategic clients on public and private mergers, acquisitions, divestitures, tender offers, joint ventures, corporate restructurings, co-investments and general corporate matters. He also assists private equity funds with the purchase, ongoing representation, and sale of portfolio companies. Shaitanoff represents clients investing in a variety of industries, including technology, life sciences, healthcare, financial services, and real estate.
“Goodwin is a recognized leader in the private equity and M&A space, and I am excited to join such a great platform,” said Shaitanoff. “I look forward to working as part of the firm’s global team to provide impactful, creative solutions to clients on complex and innovative transactions.”
Goodwin’s global Private Equity practice has grown substantially in the last 12 months, with the arrival of Josh Ratner in New York, and James Grimwood, Erik Dahl, Christian Iwasko, Sava Savov, Michelle Tong, and John Van De North, Geoff O’Dea, Hugh O’Sullivan, and Dulcie Daly in London. Goodwin now has more than 300 private equity lawyers in the U.S., Europe, and Hong Kong.
Refinitiv named Goodwin the number one firm for private equity and venture capital rounds, and the number one legal advisor (by deal count) for global M&A in 2020, representing clients on more than 650 completed transactions. Mergermarket’s Deal Drivers FY 20 reports named Goodwin the number one firm (by deal count) for Pharma, Medical, and Biotech M&A in North America; the number two firm (by value) for Pharma, Medical, and Biotech M&A in Europe, the Middle East, and Africa; and the number three firm (by deal count) for Tech, Media, and Telecoms M&A in North America. Goodwin was recently ranked highly for private equity in Chambers and Legal 500.
Source: www.goodwinlaw.com
